Asked by: Layla Moran (Liberal Democrat - Oxford West and Abingdon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to evaluate the effectiveness of NHS weight management programmes.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department of Health and Social Care, through the National Institute for Health and Care Research (NIHR), has commissioned a range of research to evaluate the effectiveness of NHS weight management programmes.
This includes an evaluation of the NHS Digital Weight Management Programme, which reported in April 2024 and found it to be highly cost-effective service, helping people to lose a clinically meaningful amounts of weight. There is also a £1.7 million evaluation commencing looking at NHS England’s new service models to deliver weight loss drugs outside of hospital settings. It will provide evidence on the effectiveness of the models to support wider roll out. It is expected to report around 2028. In addition, there is a £1.4 million evaluation of NHS England’s Complications of Excess Weight clinics, which deliver tailored support to children and young people with severe or complex forms of obesity. The evaluation will provide evidence on optimal models of care to support future expansion of the clinics and is expected to report around 2026. There is also a range of other ongoing research relevant to weight management services, including looking at services for people with depression and looking at weight regain.
The National Institute for Health and Care Excellence has also undertaken an evaluation of digital technologies delivering multidisciplinary weight-management services either with or without prescribing and monitoring obesity medicines. This was published in October 2023 and recommended the technologies that can be used in the NHS while more evidence is generated.
Asked by: Layla Moran (Liberal Democrat - Oxford West and Abingdon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to integrate mental health support into weight management services.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Institute for Health and Care Excellence (NICE) produces evidence-based guidance for service commissioners, providers, and health and care practitioners on best practice for weight management. Its guidance on weight management makes a number of recommendations about mental health support. For example, it recommends that:
- For adults, providers of weight management services discuss with a person accessing weight management services whether their individual circumstances such as psychological factors may affect their ability to lose weight, and whether referral to another service (such as mental health support) may be appropriate.
- For children, practitioners make a referral to the local mental health pathway if there are concerns that the child or young person's mental wellbeing is affected by their weight, that mental health is affecting their weight or the circumstances that influence their weight, or an eating disorder is suspected.
- Specialist weight management services, commissioned by NHS integrated care boards, should be provided by multidisciplinary teams, with psychological and behavioural support.
More recently, NHS England has issued commissioning guidance for the use of tirzepatide for the management of obesity. It states that prescribers should carefully consider the patient’s overall wellbeing, particularly when eating disorders, body dysmorphia, or mental health status are factors in the request and consideration for treatment. Onward referral to dedicated services may be made where appropriate, in line with local guidelines and existing NICE guidance.
Asked by: Andrew Snowden (Conservative - Fylde)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he has taken to ensure post-market surveillance of NHS-provided weight loss drugs to monitor their long-term effects in patients.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The newest obesity medicines, liraglutide, under various brand names, semaglutide, under the brand name Wegovy, and tirzepatide, under the brand name Mounjaro, have only been licensed and recommended for use for the treatment of obesity over the last few years. We recognise the need to collect long-term data on both the effectiveness and side effects of these medicines.
The Medicines and Healthcare products Regulatory Agency (MHRA) continually monitors the safety of medicines during their use, including weight loss medications. The MHRA has robust safety monitoring and surveillance systems in place for all healthcare products.
For example, although semaglutide and some other GLP-1 treatments have been used in the treatment of diabetes for some-time, semaglutide, when used for weight management, as well as newer medicines like tirzepatide are subject to more intense monitoring by the MHRA as part of its Black Triangle scheme.
The MHRA also strongly encourages patients and healthcare professionals to continue reporting suspected side effects to GLP-1 medicines through its Yellow Card Scheme, which collects reports of suspected adverse effects for all healthcare products.
In addition, NHS England is working with the National Institute for Health and Care Excellence, the MHRA, and academic partners to collect real world evidence on the use of tirzepatide in National Health Services. This includes monitoring prescribing patterns, patient outcomes, and long-term safety signals through existing national datasets and local system level services.
These measures ensure that the benefits and risks of using medicines for weight management are kept under ongoing review, and that appropriate action can be taken if safety concerns arise.
Asked by: Lisa Smart (Liberal Democrat - Hazel Grove)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of the NHS eligibility criteria for tirzepatide on levels of access to treatment for people (a) with obesity and (b) who do not meet the current BMI threshold but may still be at clinical risk from excess weight.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The eligibility criteria for tirzepatide, under brand name Mounjaro, for the management of weight have been set independently by the National Institute for Health and Care Excellence (NICE) following a full appraisal of the clinical and cost effectiveness of the drug. NICE’s recommendations are based on the best available evidence and ensure that National Health Service treatments are targeted at those most likely to benefit, while also protecting the overall affordability and sustainability of NHS services.
In line with NICE guidance and recommendations, the NHS in England is undertaking a phased roll out. This is based on prioritisation led by clinical need. Patient eligibility will increase in stages, up to approximately 220,000 patients after the first three years, as outlined in NHS England's Interim Commissioning Guidance, which is available at the following link:
The total eligible population should have access within the maximum period of 12 years but, as part of the rollout plans, the NHS will look at different service models, including digital and community options. New approaches might enable access to be expanded more quickly. Progress will be reviewed in three years. NHS England is actively monitoring uptake and service readiness to inform future decisions.
In addition, the 10-Year Health Plan sets out our ambition to build on these plans by testing innovative models of delivering weight loss services and treatments to patients. On 12 August we announced an £85 million competition to fund the design and delivery of new community and primary care weight management pathways to support access to interventions such as weight loss medications. We expect tens of thousands of patients to directly benefit from increased access to interventions, such as GLP-1s. This will generate new evidence to inform the future commissioning and rollout of tirzepatide.
Patients who do not meet the current body mass index threshold for tirzepatide under the NHS prioritisation approach will not be eligible for receiving tirzepatide. However, they do have access to other weight management support, if they are eligible. This could include the NHS Digital Weight Management Programme, the NHS Diabetes Prevention Programme, the NHS Type 2 Diabetes Path to Remission Programme, and other services that may be available locally.
Asked by: Laurence Turner (Labour - Birmingham Northfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to NHS England’s publication entitled Interim commissioning guidance: Implementation of the NICE Technology Appraisal TA1026 and the NICE funding variation for tirzepatide (Mounjaro) for the management of obesity, published on 27 March 2025, what estimate (a) NHS England and (b) the National Institute for Health and Care Excellence have made of the number of patients eligible for Mounjaro in each year from 2025-26 to 2027-28.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing evidence-based guidance for the National Health Service on the use of licensed medicines based on an assessment of their clinical and cost-effectiveness. NICE published the estimated total eligible population for tirzepatide for obesity (Mounjaro) in its technology appraisal, with the code TA 1026, which is available at the following link:
https://www.nice.org.uk/guidance/ta1026
The following table shows the estimated total eligible population for tirzepatide for obesity, from 2025/26 to 2028/29:
Year | Population |
Current year (2025/26) | 3,600,000 |
Year 1 (2026/27) | 3,640,000 |
Year 2 (2027/28) | 3,670,000 |
Year 3 (2028/29) | 3,700,000 |
The figures are based on the population estimated to have an initial body mass index (BMI) of at least 35, and with at least one weight-related comorbidity. They include the impact of the predicted population growth, but they do not include potential increases in obesity prevalence, or include the 2.5 BMI unit reduction that is recommended for people from certain ethnic minority backgrounds.
From 23 June, tirzepatide has started to become available in primary care, meaning it can be prescribed by general practitioners, or other competent prescribers. NHS England’s phased rollout within primary care will prioritise those with the greatest clinical need. The NHS is undertaking a phased roll out, as agreed with NICE. This is based on prioritisation led by clinical need. Patient eligibility will increase in stages, up to approximately 220,000 patients after the first three years, as outlined in NHS England's Interim Commissioning Guidance, which is available at the following link:
The total eligible population should have access within the maximum period of 12 years but, as part of the rollout plans, the NHS will look at different service models, including digital and community options. New approaches might enable access to be expanded more quickly. Progress will be reviewed in three years. In addition, the 10-Year Health Plan sets out our ambition to build on these plans by testing innovative models of delivering weight loss services and treatments to patients. On 12 August we announced an £85 million competition to fund the design and delivery of new community and primary care weight management pathways to support access to interventions such as weight loss medications. We expect tens of thousands of patients to directly benefit from increased access to interventions, such as GLP-1s. This will generate new evidence to inform the future commissioning and rollout of tirzepatide.
Asked by: Navendu Mishra (Labour - Stockport)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to provide preventative health services in Stockport constituency's most deprived wards.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government’s mission is to halve the gap in healthy life expectancy between rich and poor, through the Health Mission and 10-Year Health Plan. Our 10-Year Health Plan sets out how a shift to prevention will deliver healthier, more prosperous lives for all, but particularly for those suffering the consequences of widening levels of health inequality.
Our landmark Tobacco and Vapes Bill will help deliver our ambition for a smoke-free UK and we will take decisive action to tackle the obesity crisis and create the healthiest generation of children ever, working in partnership with schools, supermarkets, and pharmaceutical companies.
We will also be asking the NHS to do more on secondary prevention, including through strengthening its vaccination and screening programmes.
The public health grant is paid to local authorities and is used to provide vital preventative services that help to support health. In 2025/26, funding for all local authorities through the public health grant will be £3.884 billion. This is an average 3.4% real terms increase in local authority public health grant funding, compared to 2024/25. This is complemented by almost £490 million of additional targeted investment in local drug and alcohol treatment, early years and stop smoking services. This represents a significant turning point for local public health services, marking the biggest real-terms increase after nearly a decade of reduced spending. Our Regional Team works with and supports North West local authorities across a wide range of portfolios that support taking action on health inequalities including children's services, smoking cessation, drug and alcohol services, physical activity and obesity, mental wellbeing, work and health, wider determinants of health and health literacy.
Asked by: Andrew Snowden (Conservative - Fylde)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help ensure that people prescribed weight loss medication also adopt lifestyle changes.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Weight loss medications (semaglutide, tirzepatide and liraglutide) are licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) and recommended by the National Institute for Health and Care Excellence (NICE) as clinically and cost-effective treatment options on the NHS for obesity. Both the license and NICE guidance for these medicines specify that they should be prescribed alongside a reduced calorie diet and physical activity. NICE guidance also states that healthcare professionals should arrange information, support, and counselling on additional diet, physical activity, and behavioural strategies when these medicines are prescribed.
Integrated care boards (ICBs) are responsible for commissioning health services within their area in line with local population need and taking account of relevant guidance. This includes services to support lifestyle changes alongside the prescription of these medicines. NHS England have however also made a central wraparound service available which ICBs can use to support primary care prescription of these medicines. This central service focuses on nutrition, physical activity and psychological support.
Private prescribers do not have to follow NHS or NICE guidance. However, they are expected to take account of appropriate professional guidance. This includes guidance from the General Medical Council which encourages the prescription of medicines in accordance with the terms of their license unless the prescriber concludes that they should go outside of the licence for medical reasons.
Asked by: Navendu Mishra (Labour - Stockport)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help reduce differences in life expectancy between different areas within the Stockport constituency.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The UK faces significant health inequalities, with life expectancy and healthy life expectancy varying widely across and between communities. Our 10-Year Health Plan sets out a reimagined service designed to tackle inequalities in both access and outcomes, to ensure the NHS is there for anyone who needs it whenever they need it.
The Office for Health Improvement and Disparities (OHID) North West (the Regional Team) operates across the North West of England, covering the geography of Cumbria, Lancashire, Greater Manchester, Cheshire and Merseyside and serving a population of 7.5 million people.
The Regional Team works with and supports North West local authorities across a wide range of portfolios that support taking action on health inequalities. These include 0-19 services, smoking cessation, drug and alcohol services, physical activity and obesity, mental wellbeing, work and health, wider determinants of health and health literacy.
In addition, the public health grant is paid to local authorities and is used to improve population health, prevent illness, and reduce health inequalities.
Asked by: Afzal Khan (Labour - Manchester Rusholme)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to Nutrition North’s report entitled Food, Health and Nutrition in the North of England: Inequalities and opportunities published on 22 July 2025, what steps the Department is taking to help tackle (a) poverty and (b) childhood obesity in the North of England.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is committed to supporting people to stay healthier for longer. This includes tackling the determinants that underpin stark health inequalities to halve the gap in healthy life expectancy between the richest and poorest regions.
Tackling child poverty is at the heart of the Government’s mission to break down barriers to opportunity and its commitment to raising the healthiest generation of children in history. The Department is working closely with the Child Poverty Taskforce to develop and deliver an ambitious strategy to reduce child poverty, tackle the root causes, and give every child the best start in life. An important part of this will be alleviating the negative experience of living in poverty through supporting families and enhancing public services.
The 10-Year Health Plan outlines a range of actions to address childhood obesity. This includes restricting junk food advertising targeted at children, banning the sale of high-caffeine energy drinks to under-16-year-olds, and using our revised National Planning Policy Framework to give local councils stronger powers to block new fast-food outlets near schools. We will work with the Department for Education to update school food standards. To support families, we are expanding free school meals to all children with a parent in receipt of universal credit. By the end of the Parliament, we will introduce mandatory healthy food sales reporting for all large companies in the food sector.
Healthy Start is a demand-led, statutory scheme and aims to support those in greatest need. As part of the 10-Year Health Plan we announced that we will uplift the value of weekly payments by 10%, boosting the ability to buy healthy food for those families who need it most. From April 2026, pregnant women and children aged over one and under four years old will each receive £4.65 per week, up from £4.25, and children under one years old will receive £9.30 per week, up from £8.50.
The Office for Health Improvement and Disparities’ regional teams support and work towards the Government’s Opportunity and Health Missions to give children the best start in life. The teams recognise the Food, Health and Nutrition in the North of England report and strive to address the challenges and inequalities our children and young people face in the region. Regional teams work closely with local partners, including local authorities and the National Health Service, to support them with local initiatives to promote a healthy lifestyle and tackle obesity.
Asked by: Afzal Khan (Labour - Manchester Rusholme)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help tackle childhood obesity rates in the North of England.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is committed to supporting people to stay healthier for longer. This includes tackling the determinants that underpin stark health inequalities to halve the gap in healthy life expectancy between the richest and poorest regions.
Tackling child poverty is at the heart of the Government’s mission to break down barriers to opportunity and its commitment to raising the healthiest generation of children in history. The Department is working closely with the Child Poverty Taskforce to develop and deliver an ambitious strategy to reduce child poverty, tackle the root causes, and give every child the best start in life. An important part of this will be alleviating the negative experience of living in poverty through supporting families and enhancing public services.
The 10-Year Health Plan outlines a range of actions to address childhood obesity. This includes restricting junk food advertising targeted at children, banning the sale of high-caffeine energy drinks to under-16-year-olds, and using our revised National Planning Policy Framework to give local councils stronger powers to block new fast-food outlets near schools. We will work with the Department for Education to update school food standards. To support families, we are expanding free school meals to all children with a parent in receipt of universal credit. By the end of the Parliament, we will introduce mandatory healthy food sales reporting for all large companies in the food sector.
Healthy Start is a demand-led, statutory scheme and aims to support those in greatest need. As part of the 10-Year Health Plan we announced that we will uplift the value of weekly payments by 10%, boosting the ability to buy healthy food for those families who need it most. From April 2026, pregnant women and children aged over one and under four years old will each receive £4.65 per week, up from £4.25, and children under one years old will receive £9.30 per week, up from £8.50.
The Office for Health Improvement and Disparities’ regional teams support and work towards the Government’s Opportunity and Health Missions to give children the best start in life. The teams recognise the Food, Health and Nutrition in the North of England report and strive to address the challenges and inequalities our children and young people face in the region. Regional teams work closely with local partners, including local authorities and the National Health Service, to support them with local initiatives to promote a healthy lifestyle and tackle obesity.